These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35285867)

  • 21. Exertional Heat Stroke and Susceptibility to Malignant Hyperthermia in an Athlete: Evidence for a Link?
    Poussel M; Guerci P; Kaminsky P; Heymonet M; Roux-Buisson N; Faure J; Fronzaroli E; Chenuel B
    J Athl Train; 2015 Nov; 50(11):1212-4. PubMed ID: 26565425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Malignant Hyperthermia Susceptibility and Fitness for Duty.
    Lee MA; McGlinch EB; McGlinch MC; Capacchione JF
    Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strenuous exercise triggers a life-threatening response in mice susceptible to malignant hyperthermia.
    Michelucci A; Paolini C; Boncompagni S; Canato M; Reggiani C; Protasi F
    FASEB J; 2017 Aug; 31(8):3649-3662. PubMed ID: 28465322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the pathogenicity of RYR1 variants in malignant hyperthermia.
    Merritt A; Booms P; Shaw MA; Miller DM; Daly C; Bilmen JG; Stowell KM; Allen PD; Steele DS; Hopkins PM
    Br J Anaesth; 2017 Apr; 118(4):533-543. PubMed ID: 28403410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome.
    Witting N; Laforêt P; Voermans NC; Roux-Buisson N; Bompaire F; Rendu J; Duno M; Feillet F; Kamsteeg EJ; Poulsen NS; Dahlqvist JR; Romero NB; Fauré J; Vissing J; Behin A
    Acta Neurol Scand; 2018 May; 137(5):452-461. PubMed ID: 29635721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Next-generation DNA sequencing of a Swedish malignant hyperthermia cohort.
    Broman M; Kleinschnitz I; Bach JE; Rost S; Islander G; Müller CR
    Clin Genet; 2015 Oct; 88(4):381-5. PubMed ID: 25256590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using exome data to identify malignant hyperthermia susceptibility mutations.
    Gonsalves SG; Ng D; Johnston JJ; Teer JK; Stenson PD; Cooper DN; Mullikin JC; Biesecker LG;
    Anesthesiology; 2013 Nov; 119(5):1043-53. PubMed ID: 24195946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multigenerational Brazilian family with malignant hyperthermia and a novel mutation in the RYR1 gene.
    Matos AR; Sambuughin N; Rumjanek FD; Amoedo ND; Cunha LB; Zapata-Sudo G; Sudo RT
    Braz J Med Biol Res; 2009 Dec; 42(12):1218-24. PubMed ID: 19918671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idiopathic hyperCKemia and malignant hyperthermia susceptibility.
    Santos JM; Andrade PV; Galleni L; Vainzof M; Sobreira CFR; Schmidt B; Oliveira ASB; Amaral JLG; Silva HCA
    Can J Anaesth; 2017 Dec; 64(12):1202-1210. PubMed ID: 28952030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RYR1-related myopathies: a wide spectrum of phenotypes throughout life.
    Snoeck M; van Engelen BG; Küsters B; Lammens M; Meijer R; Molenaar JP; Raaphorst J; Verschuuren-Bemelmans CC; Straathof CS; Sie LT; de Coo IF; van der Pol WL; de Visser M; Scheffer H; Treves S; Jungbluth H; Voermans NC; Kamsteeg EJ
    Eur J Neurol; 2015 Jul; 22(7):1094-112. PubMed ID: 25960145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia-Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability.
    Ibarra Moreno CA; Kraeva N; Zvaritch E; Jungbluth H; Voermans NC; Riazi S
    Anesth Analg; 2023 Mar; 136(3):569-577. PubMed ID: 36201369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for mutations in the RYR1 gene in families with malignant hyperthermia.
    Muniz VP; Silva HC; Tsanaclis AM; Vainzof M
    J Mol Neurosci; 2003; 21(1):35-42. PubMed ID: 14500992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A rare genetic variant of the ryanodine receptor in a suspected malignant hyperthermia susceptible patient.
    MacKay EJ; Wilkerson C; Kraeva N; Rosenberg H; Kennedy T
    J Clin Anesth; 2016 Sep; 33():144-6. PubMed ID: 27555149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of malignant hyperthermia in patients carrying a variant in the skeletal muscle ryanodine receptor 1 gene.
    Janssens L; De Puydt J; Milazzo M; Symoens S; De Bleecker JL; Herdewyn S
    Neuromuscul Disord; 2022 Dec; 32(11-12):864-869. PubMed ID: 36283893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of genetic mutations in Australian malignant hyperthermia families using sequencing of RYR1 hotspots.
    Gillies RL; Bjorksten AR; Davis M; Du Sart D
    Anaesth Intensive Care; 2008 May; 36(3):391-403. PubMed ID: 18564801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of variants of the ryanodine receptor type 1 in patients with exertional heat stroke and positive response to the malignant hyperthermia in vitro contracture test.
    Roux-Buisson N; Monnier N; Sagui E; Abriat A; Brosset C; Bendahan D; Kozak-Ribbens G; Gazzola S; Quesada JL; Foutrier-Morello C; Rendu J; Figarella-Branger D; Cozonne P; Aubert M; Bourdon L; Lunardi J; Fauré J
    Br J Anaesth; 2016 Apr; 116(4):566-8. PubMed ID: 26994242
    [No Abstract]   [Full Text] [Related]  

  • 37. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
    Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K
    Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic epidemiology of malignant hyperthermia in the UK.
    Miller DM; Daly C; Aboelsaod EM; Gardner L; Hobson SJ; Riasat K; Shepherd S; Robinson RL; Bilmen JG; Gupta PK; Shaw MA; Hopkins PM
    Br J Anaesth; 2018 Oct; 121(4):944-952. PubMed ID: 30236257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unexpected MH deaths without exposure to inhalation anesthetics in pediatric patients.
    Brandom BW; Muldoon SM
    Paediatr Anaesth; 2013 Sep; 23(9):851-4. PubMed ID: 23848295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Core myopathies and malignant hyperthermia susceptibility: a review.
    Brislin RP; Theroux MC
    Paediatr Anaesth; 2013 Sep; 23(9):834-41. PubMed ID: 23617272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.